Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Cerilliant
Merck
Healthtrust
Accenture
Johnson and Johnson
Moodys
Harvard Business School

Generated: January 22, 2019

DrugPatentWatch Database Preview

Naproxen sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for naproxen sodium and what is the scope of naproxen sodium freedom to operate?

Naproxen sodium is the generic ingredient in nine branded drugs marketed by Bionpharma Inc, Puracap Pharm Llc, Alvogen Malta, Actavis Labs Fl Inc, Bayer, Atnahs Pharma Us, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Mylan, Novelgenix Theraps, Perrigo, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sun Pharm Inds Ltd, Teva, Teva Pharms, Watson Labs, Mylan Pharms Inc, Sun Pharma Global, and Pernix Ireland Ltd, and is included in forty-four NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naproxen sodium has fifteen patent family members in thirteen countries.

There are forty-two drug master file entries for naproxen sodium. One hundred and fifty-nine suppliers are listed for this compound.

Pharmacology for naproxen sodium
Synonyms for naproxen sodium
(-)-Naproxen sodium
(-)-Sodium (S)-6-methoxy-alpha-methyl-2-naphthaleneacetate
(2S)-2-(6-Methoxy-2-naphthyl)propanoic acid sodium salt
(2s)-2-(6-methoxy(2-naphthyl))propanoic acid sodium salt
(S)-6-Methoxy-|A-methyl-2-naphthaleneacetic acid sodium salt
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid sodium
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid sodium salt
(S)-Naproxen Sodium Salt
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, sodium salt, (S)-
2-NAPHTHALENEACETIC ACID, 6-METHOXY-alpha-METHYL-, SODIUM SALT, L-(-)-
26159-34-2
59N342
9TN87S3A3C
A-Nox
A818221
AB0013373
AB2000172
AC1Q1V3H
AK163551
AKOS015895696
AKOS015994759
Anapran
Anaprotab
Anaprox
Anaprox (TN)
ANAPROX DS
API0003516
Apo-Napro-NA
Aprol
Aprowell
Axer Alfa
BAY H6689
BAYH6689
BCP0726000300
BCP9000977
BIM-0050769.0001
C-15574
C14H13NaO3
C14H13O3.Na
CAS-26159-34-2
Causalon Pro
CC-32459
CCG-101082
CDBRNDSHEYLDJV-FVGYRXGTSA-M
CHEBI:7477
CHEMBL1200806
CPD000058746
CS-2162
CTK8G1633
D00970
D09CGL
Daio-Orengedokuto (DOT)
Diocodal
DSSTox_CID_25576
DSSTox_GSID_45576
DSSTox_RID_80973
DTXSID7045576
Dysmenalgit
EINECS 247-486-2
EU-0100792
Flanax
Flogen
Floginex
Flogogin
Floneks
Floxalin
FT-0630524
Gibinap
Gibixen
H939
HMS1570O04
HMS2052G05
HMS2230D08
HMS3262O06
HMS3269J19
HY-15030A
J10445
Kapnax
Karoksen
KS-00000XJS
KS-5141
L-(-)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid sodium salt
Laser
Leniartril
Lopac-M-1275
LP00792
LS-94350
M 1275
MFCD00058507
Miranax
MLS000069555
MLS001076076
MLS001424214
MolPort-003-849-327
Monarit
Naprelan
Naprium
Naprodil
Naprodol
Naprovite
Naproxen (Aleve)
Naproxen (sodium)
Naproxen natrium
Naproxen sodium (USP)
Naproxen sodium [USAN:USP]
Naproxen sodium [USAN]
Naproxen sodium salt
Naproxen sodium, 98.0-102.0%
Naproxen sodium, meets USP testing specifications
Naproxen sodium, pharmaceutical secondary standard; traceable to USP
Naproxen sodium, United States Pharmacopeia (USP) Reference Standard
NAPROXEN SODIUM,98%
Naproxensodium
Naprux
Naprux Gesic
Natrioxen
NC00332
NCGC00016166-01
NCGC00016759-04
NCGC00017097-01
NCGC00017097-02
NCGC00094127-01
NCGC00261477-01
Nixal
Opera_ID_1200
Opraks
OR249863
Pactens
Prexan
Primeral
Proxen
PubChem19878
RS 3650
RS-3650
S1626
SAM001246874
SCHEMBL7361
SMR000058746
Sodimax
Sodium (-)-2-(6-methoxy-2-naphthyl)propionate
sodium (2S)-2-(6-methoxy-2-naphthalenyl)propanoate
sodium (2S)-2-(6-methoxy-2-naphthyl)propanoate
sodium (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
sodium (S)-2-(6-methoxy-2-naphthyl)propionate
sodium (S)-2-(6-methoxynaphthalen-2-yl)propanoate
sodium naproxen
sodium;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
ST51052889
Sunprox
Synflex
Tandax
Topcare all day pain relief
Tox21_110774
Tox21_110774_1
Tox21_500792
UNII-9TN87S3A3C
UNM-0000306098
VA11355
Veradol
W-107195
Xenar

US Patents and Regulatory Information for naproxen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074198-002 Dec 21, 1993 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sandoz NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074495-002 Dec 5, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Contract Pharmacal NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074635-001 Jan 13, 1997 OTC No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hamilton Pharms NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074106-002 Aug 31, 1993 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glenmark Pharms Ltd NAPROXEN SODIUM naproxen sodium TABLET;ORAL 078314-002 Apr 27, 2007 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for naproxen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen Malta NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-001 Jan 5, 1996 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us ANAPROX DS naproxen sodium TABLET;ORAL 018164-003 Sep 30, 1987 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us ANAPROX naproxen sodium TABLET;ORAL 018164-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us ANAPROX DS naproxen sodium TABLET;ORAL 018164-003 Sep 30, 1987 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us ANAPROX naproxen sodium TABLET;ORAL 018164-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Alvogen Malta NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-002 Jan 5, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for naproxen sodium

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012000051 Germany ➤ Sign Up PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
C/GB11/015 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
90013-1 Sweden ➤ Sign Up PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
2012 00035 Denmark ➤ Sign Up PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
11/016 Ireland ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
2011005 Lithuania ➤ Sign Up PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
McKinsey
Moodys
Julphar
Johnson and Johnson
Teva
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.